Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis

Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Quint, Tamara, Brunner, Patrick M., Sinz, Christoph, Steiner, Irene, Ristl, Robin, Vigl, Kornelia, Kimeswenger, Susanne, Neubauer, Katharina, Pirkhammer, Detlev, Zikeli, Martin, Hoetzenecker, Wolfram, Reider, Norbert, Bangert, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230957/
https://www.ncbi.nlm.nih.gov/pubmed/32344789
http://dx.doi.org/10.3390/jcm9041241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230957/
https://www.ncbi.nlm.nih.gov/pubmed/32344789
http://dx.doi.org/10.3390/jcm9041241

Ejemplares similares